New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
12:24 EDTRNAProsensa accelerated or conditional approvals likely, says Roth Capital
Roth Capital said its is "increasingly optimistic" that regulators won't focus on the outcome of Prosensa's disappointing phase 3 study for drisapersen and are likely to consider the totality of the data given the rare disease setting. The firm believes accelerated or conditional approvals for the drug are likely and it reiterates its Buy and $17 price target on the stock.
News For RNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
06:50 EDTRNAProsensa upgraded to Overweight from Underweight at JPMorgan
JPMorgan upgraded Prosensa two notches to Overweight citing a favorable risk/reward around the potential approval of Drisapersen for Duchenne muscular dystrophy. The firm believes regulatory risk for the drug has been significantly reduced in both the U.S. and Europe. JPMorgan raised its price target for shares to $18 from $4.40.
October 10, 2014
10:12 EDTRNAProsensa begins NDA submission to FDA for drisapersen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use